Microbiology & Infectious Diseases

Three monoclonal antibodies targeting monkeypox A35 protein protect mice and improve outcomes, highlighting potential for new therapies.

A new study suggests that the common cold may boost children’s antiviral defences, lowering the risk and severity of COVID-19.

FMT and microbiome therapies significantly outperform antibiotics in recurrent C. difficile infection, with cure rates up to 91% and favourable long-term safety.

Respiratory viruses such as influenza and SARS-CoV-2 can awaken dormant breast cancer cells, driving metastasis and raising mortality risk in cancer survivors, new research finds.

A Ugandan trial has found artemether-lumefantrine less effective than other ACTs, with malaria resistance mutations linked to delayed parasite clearance.

A Phase 1 USA trial finds novel oral polio vaccines nOPV1 and nOPV3 to be safe, highly immunogenic, and comparable to Sabin-strain vaccines, paving the way for Phase 2 studies.

Portable $2 test detects deadly infections from a drop of blood within 15 minutes, with unmatched sensitivity.

An AI-driven drug discovery platform has created new antibiotics with unique mechanisms against drug-resistant N. gonorrhoeae and MRSA, showing success in preclinical models.